<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00501657</url>
  </required_header>
  <id_info>
    <org_study_id>061025</org_study_id>
    <nct_id>NCT00501657</nct_id>
  </id_info>
  <brief_title>Effects of Sitagliptin on Gastric Emptying in Healthy Subjects</brief_title>
  <official_title>Effects of Sitagliptin on Gastric Emptying in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Adelaide Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Adelaide Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of the drug, sitagliptin, on the rate
      at which the stomach empties, and the release of gut hormones and blood glucose
      concentrations, after a mashed potato meal in healthy subjects. Sitagliptin has been shown to
      reduce the blood glucose (sugar) response to a meal and this may potentially be due to
      slowing of stomach emptying. This is particularly relevant to people who have diabetes, in
      whom normalization of elevated blood glucose levels is important to maintain health.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the effect of sitagliptin on gastric emptying,
      intragastric meal distribution, postprandial glycemia and insulinemia in healthy subjects.
      Glucagon-like peptide-1 (GLP-1) inhibits gastric emptying, thereby slowing the delivery of
      nutrients, and their absorption, across the small intestine. The rate of entry of
      carbohydrate into the small intestine is especially important in patients with diabetes
      mellitus. Sitagliptin is an orally administered inhibitor of dipeptidyl-peptidase-IV
      (DPP-IV), the enzyme responsible for the degradation of GLP-1. It is hypothesized that
      sitagliptin will increase the GLP-1 response to, and thereby slow gastric emptying and
      diminish the glycemic response to, a carbohydrate-containing meal.

      Fifteen healthy subjects (male and female) will be studied. Each subject will be studied on
      two occasions following treatment for 2 days with sitagliptin (100mg once daily) or matching
      placebo in a randomized, double blind, crossover design. Measurements of gastric emptying,
      intragastric meal distribution, blood glucose concentrations, gut hormones and appetite will
      be measured for 4 hours following ingestion of a mashed potato meal.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastric emptying rate</measure>
    <time_frame>4 hours per study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intragastric distribution, gastrointestinal hormone release (GLP-1, GIP), glycemia, insulinemia, appetite</measure>
    <time_frame>4 hours per study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Gastroparesis</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Sitagliptin (100mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active drug (sitagliptin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (sugar pill)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inactive drug (placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>100mg mane for 2 days</description>
    <arm_group_label>Sitagliptin (100mg)</arm_group_label>
    <other_name>MK-0431-075</other_name>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>100mg mane for 2 days</description>
    <arm_group_label>Placebo (sugar pill)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female (females must be using an appropriate contraceptive method)

          -  18 - 45 years

          -  Body mass index (BMI) 19 - 25 kg/m2.

        Exclusion criteria:

          -  Subjects with gastrointestinal disease, history of gastrointestinal surgery and/or
             significant gastrointestinal symptoms

          -  Subjects taking medication known to influence gastrointestinal function

          -  Alcohol intake &gt; 20 g per day

          -  Smoking &gt; 10 cigarettes per day

          -  Pregnant and/or lactating females

          -  Calculated creatinine clearance &lt; 60 ml/min

          -  Exposure to ionising radiation for research purposes in the previous 12 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen L Jones, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Adelaide, Royal Adelaide Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Discipline of Medicine, Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/22738299</url>
    <description>Pubmed abstract</description>
  </link>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2007</study_first_submitted>
  <study_first_submitted_qc>July 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2007</study_first_posted>
  <last_update_submitted>October 27, 2015</last_update_submitted>
  <last_update_submitted_qc>October 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Royal Adelaide Hospital</investigator_affiliation>
    <investigator_full_name>Karen Jones</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>gastric emptying</keyword>
  <keyword>glycemia</keyword>
  <keyword>appetite</keyword>
  <keyword>incretin hormones</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

